Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline…
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…